Economic Burden of Generalized Pustular Psoriasis in Sweden: A Population-Based Register Study
Sofia Löfvendahl,Jenny M Norlin,Marcus Schmitt-Egenolf
DOI: https://doi.org/10.2147/PTT.S359011
2022-05-06
Psoriasis: Targets and Therapy
Abstract:Sofia Löfvendahl, 1 Jenny M Norlin, 1 Marcus Schmitt-Egenolf 2 1 The Swedish Institute for Health Economics (IHE), Lund, Sweden; 2 Department of Public Health and Clinical Medicine, Dermatology, Umeå University, Umeå, Sweden Correspondence: Marcus Schmitt-Egenolf, Department of Public Health and Clinical Medicine, Dermatology, Umeå university, Umeå, SE-901 85, Sweden, Tel +46 90 785 2875, Email Background: Generalized pustular psoriasis (GPP), which can occur with or without psoriasis vulgaris (PV), is a severe form of pustular psoriasis with potentially life-threatening symptoms. GPP is also associated with several comorbidities, which further adds to the burden of disease. This study investigates the economic burden of disease in patients with GPP. Methods: All-cause and GPP-specific healthcare resource use (inpatient stays, physician visits and drug use), as well as associated costs, were compared for year 2015 between GPP patients (n = 914) and two matched control groups representing the general population (n = 4047) and patients with PV but no GPP (n = 2556). Information on resource use for 2015 was obtained from the Swedish National Patient Register and Swedish Prescribed Drug Register, respectively. Results: All-cause inpatient stays, physician visits, and use of psoriasis-related drugs were significantly more common among GPP patients compared to both control groups. This difference was reflected in total direct cost for GPP patients (5062 euros/year) which was 3.1 and 1.8 times higher (p < 0.001) compared to the general population and PV controls, respectively. For GPP patients, the share of total cost was 22% for all-cause physician outpatient visits and 40% for all-cause inpatient stays. However, only 6.3% and 11.3% of these costs, respectively, were due to GPP-specific problems. Psoriasis-related drugs constituted 27% of total costs for GPP patients of which a large fraction (86%) was represented by biologics. Conclusion: This study demonstrates a higher economic burden for GPP patients compared to both the general population and patients with PV, with inpatient visits and use of biologic drugs as major cost driving factors. Only fractions of the costs for physician visits and inpatient stays were attributable to specific GPP problems, indicating a higher economic burden of GPP-consequences and complications. Keywords: generalised pustular psoriasis, population-based controls, direct costs, incremental analysis Generalized pustular psoriasis (GPP), which can occur with or without psoriasis vulgaris, is a severe form of pustular psoriasis affecting large areas of the skin. 1,2 The occurrence of acute flares is typical. The flares, that can be life-threatening, regularly require inpatient care. 2 The patient is often severely ill with general symptoms including fever and severe systemic inflammation. This repeating pattern may continue episodically throughout life. 3 Comorbidities may have a significant impact on treatment choices, drug interaction and the patients' health-related quality of life. Like moderate-to-severe psoriasis, GPP is associated with an increased occurrence of comorbidities compared to the general population. 4 Comorbidities that have been reported in GPP include obesity, hypertension, hyperlipidemia, diabetes, uveitis, 4–7 cholestasis, 8 joint involvement, 4–7,9,10 allergic rhinoconjunctivitis and peptic ulcer disease. 4,7 Although the prevalence of GPP is relatively low (ranging from 0.18 to 18/100,000), 11–15 the condition may still contribute considerably to the economic burden of psoriasis. Due to the chronicity and risk for comorbidities, GPP has implications not only for the individuals but also for society in terms of healthcare costs. In a recent US cost study on GPP, based on claims data, it was found that total medical costs (direct medical use and drugs) in GPP was higher compared to matched cohorts of persons from the general population and persons with psoriasis vulgaris, respectively. Noteworthy was that the rate of inpatient stays was four times higher in persons with GPP compared to matched cohorts. 16 These results are corroborated by a study from Japan, that also showed elevated healthcare resource and drug use in GPP patients compared to both population-based and psoriasis vulgaris controls. 4 However, to our knowledge, there are no published studies on costs associated with the use of healthcare resources in GPP, nor on the cost burden of GPP compared to psoriasis vulgaris with no GPP manifestations. In this context, it is important to investigate the allocation of costs related to the diagnosis of GPP and pot -Abstract Truncated-